These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 33803354)
1. Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma. Fritz V; Malek L; Gaza A; Wormser L; Appel M; Kremer AE; Thasler WE; Siebler J; Neurath MF; Hellerbrand C; Bosserhoff AK; Dietrich P Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803354 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression. Wan Z; Liu T; Wang L; Wang R; Zhang H Aging (Albany NY); 2020 Sep; 12(18):18192-18208. PubMed ID: 33021963 [TBL] [Abstract][Full Text] [Related]
3. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells. Luo L; Cai L; Luo L; Tang Z; Meng X Mol Med Rep; 2018 Jun; 17(6):8053-8060. PubMed ID: 29693700 [TBL] [Abstract][Full Text] [Related]
4. Downregulation of microRNA-143-5p is required for the promotion of odontoblasts differentiation of human dental pulp stem cells through the activation of the mitogen-activated protein kinases 14-dependent p38 mitogen-activated protein kinases signaling pathway. Wang BL; Wang Z; Nan X; Zhang QC; Liu W J Cell Physiol; 2019 Apr; 234(4):4840-4850. PubMed ID: 30362514 [TBL] [Abstract][Full Text] [Related]
5. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358 [TBL] [Abstract][Full Text] [Related]
6. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344 [TBL] [Abstract][Full Text] [Related]
7. The Ras-ERK signaling pathway regulates acetylated activating transcription factor 2 via p300 in pancreatic cancer cells. Li M; Song SW; Ge Y; Jin JY; Li XY; Tan XD Ann Transl Med; 2020 Oct; 8(19):1234. PubMed ID: 33178766 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration. Lv G; Hu Z; Tie Y; Du J; Fu H; Gao X; Zheng X Oncol Rep; 2014 Sep; 32(3):1021-8. PubMed ID: 24968707 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
10. microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit. Shi X; Liu TT; Yu XN; Balakrishnan A; Zhu HR; Guo HY; Zhang GC; Bilegsaikhan E; Sun JL; Song GQ; Weng SQ; Dong L; Ott M; Zhu JM; Shen XZ Oncogene; 2020 Aug; 39(35):5768-5781. PubMed ID: 32719439 [TBL] [Abstract][Full Text] [Related]
11. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Kabir TD; Ganda C; Brown RM; Beveridge DJ; Richardson KL; Chaturvedi V; Candy P; Epis M; Wintle L; Kalinowski F; Kopp C; Stuart LM; Yeoh GC; George J; Leedman PJ Hepatology; 2018 Jan; 67(1):216-231. PubMed ID: 28833396 [TBL] [Abstract][Full Text] [Related]
12. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option. Dietrich P; Freese K; Mahli A; Thasler WE; Hellerbrand C; Bosserhoff AK Oncotarget; 2018 Jan; 9(3):3605-3618. PubMed ID: 29423069 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683 [TBL] [Abstract][Full Text] [Related]
14. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. Xu L; Feng X; Hao X; Wang P; Zhang Y; Zheng X; Li L; Ren S; Zhang M; Xu M J Exp Clin Cancer Res; 2019 Feb; 38(1):98. PubMed ID: 30795787 [TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691 [TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. Frau M; Feo F; Pascale RM J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184 [TBL] [Abstract][Full Text] [Related]
17. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. Ouwens DM; de Ruiter ND; van der Zon GC; Carter AP; Schouten J; van der Burgt C; Kooistra K; Bos JL; Maassen JA; van Dam H EMBO J; 2002 Jul; 21(14):3782-93. PubMed ID: 12110590 [TBL] [Abstract][Full Text] [Related]
18. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882 [TBL] [Abstract][Full Text] [Related]
19. Upregulation of MicroRNA-19b predicts good prognosis in patients with hepatocellular carcinoma presenting with vascular invasion or multifocal disease. Hung CL; Yen CS; Tsai HW; Su YC; Yen CJ BMC Cancer; 2015 Oct; 15():665. PubMed ID: 26453548 [TBL] [Abstract][Full Text] [Related]
20. Activation of extracellular signal-regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. Minagawa T; Yamazaki K; Masugi Y; Tsujikawa H; Ojima H; Hibi T; Abe Y; Yagi H; Kitago M; Shinoda M; Itano O; Kitagawa Y; Sakamoto M Hepatol Res; 2020 Mar; 50(3):353-364. PubMed ID: 31702093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]